Oligoprogressive, Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Conditions
Brief summary
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Detailed description
This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary endpoint is disease control at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy. Participants will receive ablative local therapy per standard practices in addition to their systemic therapy and will be followed for up to 5 years following ablative local therapy. Participants will be assigned stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist.
Interventions
DEVICEAblative local therapy
Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Sponsors
University of California, Davis
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies: 1. Cohort A: prostate cancer 2. Cohort B: urothelial carcinoma 3. Cohort C: renal cell carcinoma 2. Provision of signed and dated informed consent form. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Age ≥18 years at time of consent. 5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy. 6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\] 7. ≤ 5 progressing or new metastatic lesions. 8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.
Exclusion criteria
1. Medical comorbidities precluding locally ablative therapies. 2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies. 3. Progressing intracranial lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with controlled disease | 3 months from the first day of ablative local therapy | Number of participants with controlled disease at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy | Up to 2 years from the first day of ablative local therapy | Number of participants experiencing grade ≥ 3 adverse events (except for hematologic and electrolyte abnormalities) attributable to ablative local therapy occurring up to 2 years from the first day of ablative local therapy |
| Median overall survival | Up to 1 year from the first day of ablative local therapy | Median overall survival stratified by primary tumor type |
| Time to treatment failure | Up to 1 year from the first day of ablative local therapy | Time to treatment failure, defined as time to change in systemic therapy or permanent discontinuation of cancer therapy |
Countries
United States
Contacts
CONTACTOffice of Clinical Research
PRINCIPAL_INVESTIGATORMamta Parikh, MD, MS
University of California, Davis
Outcome results
None listed